Nebulized Heparin in Burn Patients with Inhalation Trauma-Safety and Feasibility.
burn
heparin
inhalation trauma
nebulization
safety
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
25 Mar 2020
25 Mar 2020
Historique:
received:
12
03
2020
accepted:
20
03
2020
entrez:
29
3
2020
pubmed:
29
3
2020
medline:
29
3
2020
Statut:
epublish
Résumé
Pulmonary hypercoagulopathy is intrinsic to inhalation trauma. Nebulized heparin could theoretically be beneficial in patients with inhalation injury, but current data are conflicting. We aimed to investigate the safety, feasibility, and effectiveness of nebulized heparin. International multicenter, double-blind, placebo-controlled randomized clinical trial in specialized burn care centers. Adult patients with inhalation trauma received nebulizations of unfractionated heparin (25,000 international unit (IU), 5 mL) or placebo (0.9% NaCl, 5 mL) every four hours for 14 days or until extubation. The primary outcome was the number of ventilator-free days at day 28 post-admission. Here, we report on the secondary outcomes related to safety and feasibility. The study was prematurely stopped after inclusion of 13 patients (heparin In this prematurely stopped trial, we encountered important safety and feasibility issues related to frequent heparin nebulizations in burn patients with inhalation trauma. This should be taken into account when heparin nebulizations are considered in these patients.
Sections du résumé
BACKGROUND
BACKGROUND
Pulmonary hypercoagulopathy is intrinsic to inhalation trauma. Nebulized heparin could theoretically be beneficial in patients with inhalation injury, but current data are conflicting. We aimed to investigate the safety, feasibility, and effectiveness of nebulized heparin.
METHODS
METHODS
International multicenter, double-blind, placebo-controlled randomized clinical trial in specialized burn care centers. Adult patients with inhalation trauma received nebulizations of unfractionated heparin (25,000 international unit (IU), 5 mL) or placebo (0.9% NaCl, 5 mL) every four hours for 14 days or until extubation. The primary outcome was the number of ventilator-free days at day 28 post-admission. Here, we report on the secondary outcomes related to safety and feasibility.
RESULTS
RESULTS
The study was prematurely stopped after inclusion of 13 patients (heparin
CONCLUSION
CONCLUSIONS
In this prematurely stopped trial, we encountered important safety and feasibility issues related to frequent heparin nebulizations in burn patients with inhalation trauma. This should be taken into account when heparin nebulizations are considered in these patients.
Identifiants
pubmed: 32218127
pii: jcm9040894
doi: 10.3390/jcm9040894
pmc: PMC7230289
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Nederlandse Brandwonden Stichting
ID : 12.001
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Expert Rev Respir Med. 2009 Jun 1;3(3):283-297
pubmed: 20161170
Respir Care. 2013 Aug;58(8):1315-22
pubmed: 23232732
Respir Care. 2015 Jun;60(6):858-74; discussion 874-9
pubmed: 26070580
Trials. 2014 Mar 25;15:91
pubmed: 24661817
J Intensive Care Med. 2016 Sep;31(8):499-510
pubmed: 26112758
Ann Am Thorac Soc. 2014 Mar;11(3):425-34
pubmed: 24673698
J Burn Care Res. 2017 Jan/Feb;38(1):45-52
pubmed: 27532613
Am J Surg. 1993 Dec;166(6):592-6; discussion 596-7
pubmed: 8273836
J Burn Care Res. 2008 Jan-Feb;29(1):192-5
pubmed: 18182921
Ann Intensive Care. 2016 Dec;6(1):33
pubmed: 27083915
News Physiol Sci. 2003 Jun;18:125-9
pubmed: 12750450
Am J Respir Crit Care Med. 2011 Jul 1;184(1):106-15
pubmed: 21474643
Crit Care. 2010;14(5):R180
pubmed: 20937093
Respir Care. 2013 Jun;58(6):1053-73
pubmed: 23709200
Crit Care Med. 2012 Apr;40(4):1113-21
pubmed: 22067627
J Crit Care. 2014 Feb;29(1):182.e1-4
pubmed: 23932140
J Pharm Pract. 2019 Apr;32(2):163-166
pubmed: 29233052
Burns. 2011 Nov;37(7):1154-60
pubmed: 21816542
J Burn Care Res. 2009 Mar-Apr;30(2):249-56
pubmed: 19165116
Crit Care Med. 2014 Feb;42(2):413-9
pubmed: 24158173
J Burn Care Res. 2007 Sep-Oct;28(5):635-58
pubmed: 17969244